# A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC (Phase 1)

> **NCT04830800** · PHASE1 · COMPLETED · sponsor: **Institute of Vaccines and Medical Biologicals, Vietnam** · enrollment: 120 (actual)

## Conditions studied

- COVID-19 Disease
- SARS Pneumonia
- Pneumonia, Viral
- COVID-19 Vaccine

## Interventions

- **BIOLOGICAL:** COVIVAC
- **BIOLOGICAL:** Phosphate-buffered saline

## Key facts

- **NCT ID:** NCT04830800
- **Lead sponsor:** Institute of Vaccines and Medical Biologicals, Vietnam
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-10
- **Primary completion:** 2021-06-06
- **Final completion:** 2021-10-31
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2025-02-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04830800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04830800, "A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC (Phase 1)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04830800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*